Online citations, reference lists, and bibliographies.
← Back to Search

Topical 0.005% Tacrolimus Eye Drop For Refractory Vernal Keratoconjunctivitis

A. Kheirkhah, M. K. Zavareh, F. Farzbod, M. Mahbod, M. J. Behrouz
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
PurposeTo evaluate the efficacy and safety of topical 0.005% tacrolimus eye drop for treatment of refractory vernal keratoconjunctivitis (VKC).MethodsThis prospective study included 20 eyes of 10 patients with refractory VKC, who had active symptomatic disease despite conventional medications including topical steroids. After discontinuing all other medications, patients were treated with topical 0.005% tacrolimus eye drop four times a day. Changes in subjective symptoms and objective signs after treatment were evaluated, and development of possible complications was assessed.ResultsMean age of patients was 21.3±7.4 years and mean duration of VKC was 12.1±5.8 years. After starting tacrolimus eye drop, patients were followed for a mean duration of 10.7±3.7 months (range, 6–15 months). All symptoms including itching, redness, photosensitivity, foreign body sensation, and mucus discharge improved after the treatment; itching was the first symptom to show dramatic relief. In addition, there was improvement in objective signs including conjunctival hyperaemia, conjunctival papillary hypertrophy, giant papillae, limbal hypertrophy, corneal punctate epithelial erosions, and corneal pannus; conjunctival hyperaemia was the first sign to show improvement. No patient required addition of other medications including steroids for further relief. Any attempt to discontinue tacrolimus eye drop was associated with recurrence of patients’ symptoms and signs, necessitating continued use of the medication during the entire follow-up time. No ocular complication related to tacrolimus was noted.ConclusionTopical 0.005% tacrolimus eye drop seemed to be a safe and effective treatment for steroid-resistant refractory VKC; however, long-term use was needed to control the disease.
This paper references
Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts.
C. M. Sloper (2001)
Topical cyclosporine in vernal keratoconjunctivitis.
J. H. Bleik (1991)
Tacrolimus Ointment 0.03% in the Eye for Treatment of Giant Papillary Conjunctivitis
G. Kymionis (2008)
Use of Systemic T-lymphocyte Signal Transduction Inhibitors in the Treatment of Atopic Keratoconjunctivitis
F. Anzaar (2008)
Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats.
H. Kawashima (1988)
Vernal keratoconjunctivitis: Result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment.
P. Vichyanond (2004)
Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506.
C. Kobayashi (1989)
A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.
Y. Ohashi (2010)
Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids
H. Zribi (2009)
[The study of FK506 eye drops preventing and treating immune rejection on limbal allograft transplantation].
Jian Chen (2003)
Topical tacrolimus treatment of atopic eyelid disease.
Sarah M Rikkers (2003)
Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup.
S. Bonini (2000)
Novel immunosuppressive agent, FK506 : in vitro effects on the cloned T cell activation
澤田 新一郎 (1989)
Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis.
D. Benezra (1986)
Allergic and immunologic disorders of the eye.
L. Bielory (1992)
Effect of FK506 eye drops on late and delayed‐type responses in ocular allergy models
T. Sengoku (2003)
Effectiveness of tacrolimus in high-risk limbal allo-graft transplantation.
F. N. Yalcindag (2008)
Inhibitory effects of FK506 on the development of experimental allergic/immune-mediated blepharoconjunctivitis in Lewis rats by systemic but not by topical administration
H. Iwamoto (1999)
Preclinical and clinical study of FK506 in uveitis.
M. Mochizuki (1992)
Ocular complications of vernal keratoconjunctivitis.
K. Tabbara (1999)
Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study.
Hannele M Virtanen (2006)
Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine.
C. M. Sloper (1999)
[FK 506 ointment 0.1 % - A new therapeutic option for atopic blepharitis. Clinical trial with 14 patients].
K. Mayer (2001)
Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat.
Masakatsu Nishi (1993)
Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders.
A. Cheng (2006)
Topical Use of Cyclosporine in the Treatment of Vernal Keratoconjunctivitis
T. M. Arbab (2011)
Systemic Tacrolimus in the Treatment of Severe Atopic Keratoconjunctivitis
T. Stumpf (2006)
Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis
E. Nivenius (2007)
FK 506 ointment 0.1-A new therapeutic option for atopic blepharitis. Clinical trial with 14 patients. Mayer K, Reinhard T, Reis A, Bohringer D, Sundmacher R.∗ Klin Monatsbl Augenheilkd. 2001;218:733–736
T. Liesegang (2002)
Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases.
D. Miyazaki (2008)

This paper is referenced by
Abstract. Lipopolysaccharide (LPS)-induced keratitis is a progressive infectious ocular disease in which innate inflam- matory responses often cause clinical tissue damage and vision loss. The present study aimed to investigate the effects of tacrolimus, an effective immunomodulator, on LPS‐induced
Yu Yi-feng (2017)
Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis
Samir S Shoughy (2016)
17 – Treatment of Allergic Eye Disease
Amy T. Kelmenson (2013)
The Efficacy of Topical Interferon Alpha 2b Treatment in Refractory Vernal Keratoconjunctivitis
Ece Turan-Vural (2012)
Efectividad de la inmunoterapia con alergenos en pacientes con queratoconjuntivitis vernal
Elizabeth López-Piedrahíta (2013)
Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis.
A. Al-Amri (2014)
Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management
S. Ackerman (2016)
Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis
X. C. Wan (2014)
Topical Tacrolimus 0.03% as Sole Therapy in Vernal Keratoconjunctivitis: A Randomized Double-Masked Study
Guilherme Gubert Müller (2014)
Giant papillary conjunctivitis: A review.
Sarah E Kenny (2020)
Efficacy of Topical Tacrolimus 0.05% Suspension on Treatment of Steroid Resistant Refractory Vernal Keratoconjunctivitis
A. B. Rafii (2013)
A Biodegradable, Sustained-Released, Tacrolimus Microfilm Drug Delivery System for the Management of Allergic Conjunctivitis in a Mouse Model.
Y. Liu (2018)
Tacrolimus Loaded PEG-Cholecalciferol Based Micelles for Treatment of Ocular Inflammation
S. Kutlehria (2018)
The effects of FK506 combined with natamycin in the treatment of experimental fungal keratitis by suppressing NLRP3 inflammasome activation
L. Liang (2017)
Long-term use of topical tacrolimus ointment: a safe and effective option for the treatment of vernal keratoconjunctivitis.
Guilherme Gubert Müller (2019)
Topical Calcineurin Inhibitors: Expanding Indications for Corneal and Ocular Surface Inflammation
H. Ghasemi (2019)
Tissue Engineered Conjunctival Epithelial Transplants For The Treatment Of Ocular Surface Disorders
J. Eidet (2013)
Topical tacrolimus in anterior segment inflammatory disorders
Samir S Shoughy (2017)
Late-term topical tacrolimus for subepithelial infiltrates resistant to topical steroids and ciclosporin secondary to adenoviral keratoconjunctivitis
Ceyhun Arici (2020)
Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety
V. Öner (2012)
The Efficacy of 0.03% Dermatological Tacrolimus Ointment for Refractory Vernal Keratoconjunctivitis.
Hafiza Sadia Imtiaz (2020)
Tacrolimus for the Treatment of Subepithelial Infiltrates Resistant to Topical Steroids After Adenoviral Keratoconjunctivitis
R. Ghanem (2014)
Effect of Topical Tacrolimus in the Treatment of Thygeson's Superficial Punctate Keratitis.
Maria Carolina Marquezan (2015)
Use of Cyclosporine A and Tacrolimus in Treatment of Vernal Keratoconjunctivitis
P. Vichyanond (2013)
Prevalence of various types of allergens in ocular allergic conditions of patients from Pokhara, Nepal
S. Shrestha (2014)
Successful treatment of allergic conjunctival granuloma by topical tacrolimus: A clinicopathologic case report
A. Foroutan (2018)
Tacrolimus: An updated review on delivering strategies for multifarious diseases
Divya Dheer (2018)
Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study
H. Zanjani (2017)
Topical tacrolimus for the management of acute allergic conjunctivitis in a mouse model
I. Barequet (2013)
Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases.
Young Ji Lee (2013)
Piel y enfermedades de otros órganosOjo y piel
Jl Michel (2014)
To Assess the Efficacy and Safety of Tacrolimus Skin Cream, 0.03% in Moderate to Severe Vernal Keratoconjunctivitis
S. Irfan (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar